PE20160535A1 - Proteinas de union al receptor del factor de crecimiento epidermico (egfr) - Google Patents

Proteinas de union al receptor del factor de crecimiento epidermico (egfr)

Info

Publication number
PE20160535A1
PE20160535A1 PE2015002701A PE2015002701A PE20160535A1 PE 20160535 A1 PE20160535 A1 PE 20160535A1 PE 2015002701 A PE2015002701 A PE 2015002701A PE 2015002701 A PE2015002701 A PE 2015002701A PE 20160535 A1 PE20160535 A1 PE 20160535A1
Authority
PE
Peru
Prior art keywords
egfr
growth factor
factor receptor
epidermal growth
fragments
Prior art date
Application number
PE2015002701A
Other languages
English (en)
Inventor
Antony Wilks Burgess
Elizabeth Stockert
Peter Collins
Huei-Jen Su Huang
Terrance Grant Jonhs
Achim Jungbluth
George Mark
Anne Murray
Edouard Collins Nice
Lloyd J Old
Con Panousis
Christoph Renner
Gerd Ritter
Andrew Mark Scott
Webster K Cavanee
Original Assignee
Ludwig Inst For Cancer Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42077108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160535(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ludwig Inst For Cancer Res Ltd filed Critical Ludwig Inst For Cancer Res Ltd
Publication of PE20160535A1 publication Critical patent/PE20160535A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se refiere a miembros de union especificos, particularmente anticuerpos y fragmentos de estos, que se unen al receptor del factor de crecimiento epidermico (EGFR) amplificado y a la version truncada del EGFR de 2-7. En particular, el epitope reconocido por los miembros de union especificos, particularmente los anticuerpos y los fragmentos de estos, se ve potenciado o es evidente al haber una modificacion post-traduccional aberrante. Estos miembros de union especificos son utiles en el diagnostico y el tratamiento del cancer. Los miembros de union de la presente invencion tambien pueden usarse en la terapia, en combinacion con agentes quimioterapeuticos o anticancerosos y/o con otros anticuerpos o fragmentos de estos
PE2015002701A 2009-02-18 2010-02-17 Proteinas de union al receptor del factor de crecimiento epidermico (egfr) PE20160535A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/388,504 US20100056762A1 (en) 2001-05-11 2009-02-18 Specific binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
PE20160535A1 true PE20160535A1 (es) 2016-06-10

Family

ID=42077108

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2020000069A PE20200609A1 (es) 2009-02-18 2010-02-17 Proteinas de union al receptor del factor de crecimiento epidermico (egfr)
PE2011001515A PE20120569A1 (es) 2009-02-18 2010-02-17 Proteinas de union especificas y sus usos
PE2015002701A PE20160535A1 (es) 2009-02-18 2010-02-17 Proteinas de union al receptor del factor de crecimiento epidermico (egfr)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2020000069A PE20200609A1 (es) 2009-02-18 2010-02-17 Proteinas de union al receptor del factor de crecimiento epidermico (egfr)
PE2011001515A PE20120569A1 (es) 2009-02-18 2010-02-17 Proteinas de union especificas y sus usos

Country Status (34)

Country Link
US (6) US20100056762A1 (es)
EP (3) EP2398828B1 (es)
JP (6) JP5859314B2 (es)
KR (7) KR101921046B1 (es)
CN (3) CN104650232B (es)
AU (4) AU2010216168B2 (es)
BR (1) BRPI1012340B1 (es)
CA (1) CA2752584C (es)
CL (2) CL2011002003A1 (es)
CO (1) CO6420350A2 (es)
CY (2) CY1124849T1 (es)
DK (2) DK2398828T3 (es)
DO (1) DOP2020000032A (es)
EC (1) ECSP11011335A (es)
ES (2) ES2540802T3 (es)
GT (1) GT201100223A (es)
HK (3) HK1206752A1 (es)
HR (2) HRP20150656T1 (es)
HU (2) HUE037061T2 (es)
IL (1) IL214643A (es)
LT (1) LT2913344T (es)
MX (3) MX361876B (es)
MY (2) MY185858A (es)
NO (1) NO2913344T3 (es)
NZ (4) NZ716762A (es)
PE (3) PE20200609A1 (es)
PH (1) PH12014502419A1 (es)
PL (2) PL2913344T3 (es)
PT (2) PT2913344T (es)
RU (3) RU2673724C2 (es)
SG (3) SG173688A1 (es)
SI (2) SI2398828T1 (es)
UA (2) UA117807C2 (es)
WO (1) WO2010096434A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP2126127B1 (en) * 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CA2680854C (en) * 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US8314151B2 (en) * 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
US9029508B2 (en) * 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
BRPI0913406A2 (pt) * 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
KR20110016959A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
AU2009321508B2 (en) 2008-11-03 2015-03-12 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2012112550A (ru) * 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011100369A2 (en) * 2010-02-09 2011-08-18 The Trustees Of Columbia University In The City Of New York Methods for altering polypeptide expression and solubility
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
BR112013003257A2 (pt) * 2010-08-10 2016-06-14 Glycotope Gmbh anticorpos egfr humanizados.
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
CA2888908A1 (en) * 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
US8911992B2 (en) * 2011-04-28 2014-12-16 Bio-Rad Laboratories, Inc. DNA removal in target molecule purification
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
PT2802351T (pt) 2012-01-09 2019-06-27 Adc Therapeutics Sa Agentes para o tratamento de cancro da mama triplo negativo
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
WO2014018113A1 (en) 2012-07-24 2014-01-30 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2890720B1 (en) * 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
US20150293105A1 (en) * 2012-10-26 2015-10-15 The University Of Queensland Methods for classifying tumors and uses therefor
JP6109952B2 (ja) 2012-11-01 2017-04-05 アッヴィ・インコーポレイテッド 抗ｖｅｇｆ／ｄｌｌ４二重可変ドメイン免疫グロブリンおよびこれらの使用
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
CN104087607B (zh) * 2013-04-01 2017-06-20 科济生物医药（上海）有限公司 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞
WO2015018527A1 (en) * 2013-08-07 2015-02-12 Affimed Therapeutics Ag ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
JP6682509B2 (ja) 2014-05-14 2020-04-15 カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN106349389B (zh) * 2015-07-21 2019-11-15 科济生物医药（上海）有限公司 肿瘤特异性抗egfr抗体及其应用
US10768794B2 (en) 2015-12-21 2020-09-08 Sap Se Truncated synchronization of data object instances
US11360997B2 (en) 2015-12-21 2022-06-14 Sap Se Data synchronization error resolution based on UI manipulation actions
EP3888689A1 (en) 2016-06-08 2021-10-06 AbbVie Inc. Anti-egfr antibody drug conjugates
JP2019521106A (ja) 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
MX2018015280A (es) 2016-06-08 2019-08-12 Abbvie Inc Conjugados de anticuerpo y farmaco anti-egfr.
AU2017345574A1 (en) 2016-10-19 2019-05-23 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
EP3600302A4 (en) 2017-03-29 2020-12-30 United States Government as Represented by The Department of Veterans Affairs METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. COMPOUNDS MODULATING THE PATH OF SPHINGOSINE FOR THE TREATMENT OF CANCERS
CN108220244A (zh) * 2018-01-18 2018-06-29 东北农业大学 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
CN107974461A (zh) * 2018-01-18 2018-05-01 东北农业大学 一种高效表达anti-hEGFR基因的真核表达载体构建方法
CN108250297B (zh) * 2018-01-23 2021-07-23 上海生物制品研究所有限责任公司 抗egfr抗体、其制法及其应用
EP3941947A4 (en) * 2019-03-22 2022-12-14 Olivia Newton-John Cancer Research Institute ANTI-HER2 BINDING MOLECULES
US20230130791A1 (en) * 2020-03-11 2023-04-27 United States Government As Represented By The Department Of Veterans Affairs A Combined Inhibition of EGFR and NRF2 in The Treatment of Malignant Glioma
CN116601176A (zh) * 2020-09-30 2023-08-15 中国科学院动物研究所 靶向egfr的嵌合抗原受体
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4359440A1 (en) 2021-06-22 2024-05-01 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof

Family Cites Families (300)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US439912A (en) 1890-11-04 Shutter worker
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4162940A (en) 1977-03-31 1979-07-31 Takeda Chemical Industries, Ltd. Method for producing Antibiotic C-15003 by culturing nocardia
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
US4263294A (en) 1978-11-20 1981-04-21 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and method of use thereof
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5622790A (en) 1979-07-31 1981-03-03 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4413132A (en) 1980-11-18 1983-11-01 The Upjohn Company Antibiotic CC-1065 indoline intermediates
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
FR2523445A1 (fr) 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
US4418064A (en) 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
WO1985003357A1 (en) 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5047324A (en) 1986-12-09 1991-09-10 Miles Inc. Substantially pure enzyme-antibody conjugate preparations
US5332837A (en) 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US4937183A (en) 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5541339A (en) 1988-09-12 1996-07-30 The Upjohn Company CC-1065 analogs having two CPI subunits
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5171563A (en) 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
JPH04501266A (ja) 1988-10-12 1992-03-05 セントコアー，インコーポレーテッド ヨード―１２５で標識された放射線療法用接合体
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5013547A (en) 1989-02-07 1991-05-07 Erbamont, Inc. Anticancer drug - antibody conjugates and method for preparing same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
WO1991013356A1 (en) 1990-02-20 1991-09-05 Coulter Corporation Improved antibody-enzyme direct conjugates and method of making same
WO1991016350A1 (en) 1990-04-20 1991-10-31 Ludwig Institute For Cancer Research Aberrant, epidermal growth factor receptor dna, rna and protein forms and method
JPH05508394A (ja) 1990-04-25 1993-11-25 ファルマシア・アンド・アップジョン・カンパニー 新規なｃｃ―１０６５アナログ
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6248332B1 (en) 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
JPH04334377A (ja) 1990-12-31 1992-11-20 Akzo Nv 酸−不安定性リンカー分子
HU219537B (hu) 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6797492B2 (en) * 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
DK0586002T3 (da) 1992-08-18 2000-06-19 Centro Inmunologia Molecular Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
ES2178669T3 (es) 1994-03-07 2003-01-01 Medarex Inc Moleculas biespecificas que tienen utilidad clinica.
ES2191702T3 (es) 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
EP0796277B1 (en) 1994-11-28 2004-03-24 Thomas Jefferson University Fusion junction type iii mutant egf receptor peptide tumour vaccine
JP3607407B2 (ja) 1995-04-26 2005-01-05 株式会社日立製作所 半導体記憶装置
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
WO1997012862A1 (en) 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
US6699715B1 (en) 1995-11-30 2004-03-02 Bristol-Myers Squibb Co. Modified sFv molecules which mediate adhesion between cells and uses thereof
PT871490E (pt) 1995-12-22 2003-07-31 Bristol Myers Squibb Co Ligantes de hidrazona ramificada
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
NZ332960A (en) 1996-05-31 2000-05-26 Scripps Research Inst tetrahydro-cyclopropan[c]benz[e]-indol-4-one and tetrahydro-cyclopropan[c]benzo[e]-indole derivatives and medicaments
US5708156A (en) * 1996-05-31 1998-01-13 Ilekis; John V. Epidermal growth factor receptor-like gene product and its uses
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
EP0983248B1 (en) 1997-05-22 2004-07-14 The Scripps Research Institute Analogs of duocarmycin and cc-1065
DE69823845T2 (de) 1997-09-12 2005-04-28 Lumigen, Inc., Southfield Neue verbindungen zur erzeugung von chemilumineszenz mit hilfe einer peroxidase
AU756721B2 (en) 1997-10-14 2003-01-23 Scripps Research Institute, The iso-CBI and iso-CI analogs of CC-1065 and the duocarmycins
CA2313231A1 (en) 1997-12-08 1999-06-17 The Scripps Research Institute Synthesis of cc-1065/duocarmycin analogs
US6464686B1 (en) 1998-01-21 2002-10-15 Abbott Laboratories Polyurethane feeding tube and associated adaptors
US6355683B1 (en) 1998-09-11 2002-03-12 Ilexus Pty Limited Fc receptor modulators and uses thereof
US7553809B2 (en) 1998-02-06 2009-06-30 Ilexus Pty Limited Fc receptor modulators and uses thereof
WO1999040117A1 (en) 1998-02-06 1999-08-12 Ilexus Pty. Limited THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20030224001A1 (en) 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ES2230848T3 (es) 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
AUPP380498A0 (en) 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US20030215387A1 (en) 1998-09-04 2003-11-20 Peter Harrison Bifunctional antibodies and their use in targeting anti-tumour agents
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
KR20020000223A (ko) 1999-05-14 2002-01-05 존 비. 랜디스 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
DE60032633T2 (de) 1999-11-24 2007-10-04 Immunogen Inc., Cambridge Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung
JP2003531821A (ja) 1999-12-29 2003-10-28 イムノージェン インコーポレーテッド 改変型ドキソルビシンおよびダウノルビシンを含む細胞傷害性薬剤ならびにその治療上の使用
EP1266009B1 (en) 2000-02-25 2008-12-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
US20010046686A1 (en) 2000-03-10 2001-11-29 Wong Albert J. Sensitive detection of wild-type and mutant EGFR by specific ELISA assays in any biological sample
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
US6596302B2 (en) 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
ATE279390T1 (de) 2000-05-02 2004-10-15 Tietze Lutz F Prof Dr Neue prodrugs von 6-hydroxy-2,3-dihydro-1h- indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo 3,2- e)indolen und 5-hydroxy-1,2-dihydro-3h-benzo e)indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro- benzo f)chinolin-derivaten für eine selektive krebstherapie
CN102698265A (zh) 2000-05-19 2012-10-03 杰南技术公司 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
AUPQ841800A0 (en) 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
EP1311291A4 (en) 2000-08-09 2007-07-25 Imclone Systems Inc TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AR030612A1 (es) 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
DK1320522T3 (da) 2000-09-19 2006-04-03 Moses Lee Achirale analoger af CC-1065 og af duocarmyciner samt præparater og metoder til anvendelse deraf
DE10048417A1 (de) 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
US6849625B2 (en) 2000-10-13 2005-02-01 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
HUP0303173A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
US20020156274A1 (en) 2001-03-16 2002-10-24 Terfloth Gerald J. Process for preparing maytansinol
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
CN1507355A (zh) 2001-05-08 2004-06-23 Ĭ��ר�����޹�˾ 使用抗egfr抗体和抗激素剂的联合疗法
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002092771A2 (en) * 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
AU2002303929B9 (en) 2001-05-31 2007-01-25 E. R. Squibb & Sons, L.L.C. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1417232B1 (en) 2001-06-13 2014-12-03 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1421113A4 (en) 2001-08-03 2005-04-13 Commw Scient Ind Res Org SCREENING METHODS BASED ON CRYSTALLINE EGF RECEPTOR STRUCTURE
DE10138876B4 (de) 2001-08-08 2008-11-06 Forschungszentrum Jülich GmbH Genetisch modifizierte zyklisch-Nukleotid-gesteuerte lonenkanäle und deren Verwendung
EP1423110A4 (en) 2001-09-07 2005-04-27 Scripps Research Inst CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES
US20030109682A1 (en) 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20040241703A1 (en) 2002-08-19 2004-12-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002360413A1 (en) 2001-11-21 2003-06-10 University Of Washington Biosynthetic gene cluster for the maytansinoid antitumor agent ansamitocin
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
JP2005532258A (ja) 2002-01-03 2005-10-27 スミスクライン・ビーチャム・コーポレイション 免疫コンジュゲートの調製方法
US6790954B2 (en) 2002-01-29 2004-09-14 Immunogen, Inc. Mutant Actinosynnema pretiosum strain with increased maytansinoid production
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US20050222059A1 (en) 2002-02-25 2005-10-06 Tang Careen K Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer
US20030211112A1 (en) 2002-03-19 2003-11-13 Waldemar Debinski EGFR ligands and methods of use
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
WO2003096782A2 (en) 2002-05-13 2003-11-27 Smithkline Beecham Corporation Process for preparing maytansinol
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
JP2006508899A (ja) 2002-05-20 2006-03-16 アブジエニツクス・インコーポレイテツド ＥＧＦｒに対する抗体を使用する腎癌の治療方法
WO2005056606A2 (en) 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
JPWO2003101491A1 (ja) 2002-06-03 2005-09-29 三菱ウェルファーマ株式会社 Ｈｅｒ２又は／及びＥＧＦＲ発現又は活性化対象に用いる予防又は／及び治療剤
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
HUE027549T2 (hu) 2002-07-31 2016-10-28 Seattle Genetics Inc Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére
MXPA05001390A (es) 2002-08-02 2005-07-29 Immunogen Inc Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico.
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
CA2501818C (en) 2002-10-10 2012-03-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical compositions directed to erb-b1 receptors
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
US20040147428A1 (en) 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
EP1622941A2 (en) 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US20050026987A1 (en) 2003-05-13 2005-02-03 The Scripps Research Institute CBI analogues of the duocarmycins and CC-1065
WO2004110498A2 (en) 2003-05-14 2004-12-23 Immunogen, Inc. Drug conjugate composition
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR20120098932A (ko) 2003-06-27 2012-09-05 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP4804357B2 (ja) * 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗ｃｄ５２抗体
KR101192496B1 (ko) 2003-11-06 2012-10-18 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
SI1718677T1 (sl) 2003-12-19 2012-08-31 Genentech Inc Monovalentni protitelesni fragmenti, uporabni kot zdravila
WO2005070457A1 (en) 2004-01-23 2005-08-04 Seattle Genetics, Inc. Melphalan prodrugs
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
AU2005224267B2 (en) 2004-03-19 2011-07-21 Imclone Llc Human anti-epidermal growth factor receptor antibody
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005094357A2 (en) 2004-03-31 2005-10-13 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
WO2005099754A2 (en) 2004-04-14 2005-10-27 The Ohio State University Research Foundation Maytansinoid analogs as antitumor agents
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
CN114053429A (zh) 2004-06-01 2022-02-18 健泰科生物技术公司 抗体-药物偶联物和方法
EP1766068A4 (en) 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
ZA200701656B (en) * 2004-08-05 2008-09-25 Genentech Inc Humanized anti-cment antagonists
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2586909A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
EP1688415A1 (en) 2004-12-07 2006-08-09 Aventis Pharma S.A. Cytotoxic agents comprising new C-2 modified taxanes
US20060121044A1 (en) 2004-12-07 2006-06-08 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
WO2006086733A2 (en) 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
CN102007220A (zh) 2005-04-01 2011-04-06 安姆根有限公司 表皮生长因子受体基因拷贝数
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP1917030A4 (en) 2005-08-03 2011-03-09 Immunogen Inc IMMUNKONJUGATFORMULIERUNGEN
EP1909846B1 (en) 2005-08-05 2018-12-26 Syntarga B.V. Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation
US7598375B2 (en) 2005-08-09 2009-10-06 Millenium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2390826T3 (es) 2005-08-24 2012-11-16 Immunogen Inc Procedimiento para preparar conjugados de fármaco purificados
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
EP1940789B1 (en) 2005-10-26 2011-11-23 Medarex, Inc. Methods and compounds for preparing cc-1065 analogs
EP1945647B9 (en) 2005-11-08 2012-11-14 Immunogen, Inc. Processes for preparation of maytansinol
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
US20090306101A1 (en) 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
US7723484B2 (en) 2005-11-12 2010-05-25 Applied Molecular Evolution, Inc. Anti-EGFR antibodies
MX2008008564A (es) 2006-01-04 2009-01-29 Merck Patent Gmbh Terapeutica combinada con anticuerpos anti-egfr y anti-her2.
JP5346589B2 (ja) 2006-02-02 2013-11-20 シンタルガ・ビーブイ 水溶性ｃｃ−１０６５類似体及びその接合体
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CA2664327A1 (en) * 2006-09-15 2008-03-20 Lifescience Pharmaceuticals Method for detecting and treating skin disorders
US20110038856A1 (en) 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
US7790164B2 (en) 2006-11-14 2010-09-07 Van Andel Research Institute Fragments of antibodies to epidermal growth factor receptor and methods of their use
US20100034808A1 (en) * 2006-11-21 2010-02-11 Toru Nakazawa Compositions and methods for preserving cells of the eye
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
EP2126127B1 (en) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
WO2008152537A2 (en) 2007-06-14 2008-12-18 Zenotech Laboratories Limited Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof
US20100322939A1 (en) 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
AU2007357156B2 (en) 2007-08-01 2013-01-10 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US20090269343A1 (en) 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
AU2009243010B2 (en) 2008-04-30 2015-02-05 Immunogen, Inc. Cross-linkers and their uses
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CA3014224C (en) 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
US20110008766A1 (en) 2009-05-01 2011-01-13 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP5680087B2 (ja) 2009-09-22 2015-03-04 シャンハイ・イージェー・バイオテクノロジー・カンパニー、リミテッドＳｈａｎｇｈａｉ Ｙｉｊｉｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ 特異的結合タンパク質およびその使用
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
US20160046726A1 (en) 2016-02-18
BRPI1012340A (pt) 2017-07-25
KR20150093865A (ko) 2015-08-18
PH12014502419A1 (en) 2017-06-05
HK1206752A1 (en) 2016-01-15
CN104650232B (zh) 2018-06-05
SI2913344T1 (sl) 2017-10-30
CN102405235B (zh) 2016-02-24
US20120183471A1 (en) 2012-07-19
AU2010216168B2 (en) 2015-08-13
CN104650232A (zh) 2015-05-27
SI2398828T1 (sl) 2015-07-31
DK2398828T3 (en) 2015-04-27
CA2752584A1 (en) 2010-08-26
BRPI1012340A8 (pt) 2018-01-02
AU2015255246A1 (en) 2015-12-03
KR101579769B1 (ko) 2015-12-28
DOP2020000032A (es) 2020-02-28
US20180057606A1 (en) 2018-03-01
US20100056762A1 (en) 2010-03-04
RU2011138154A (ru) 2013-03-27
MX2011008767A (es) 2011-11-02
AU2015255246B2 (en) 2017-09-14
GT201100223A (es) 2013-11-21
KR101921046B1 (ko) 2018-11-23
CY1119591T1 (el) 2018-03-07
CL2015003090A1 (es) 2016-07-22
SG10201801945TA (en) 2018-04-27
IL214643A (en) 2016-10-31
JP2012518039A (ja) 2012-08-09
RU2673724C2 (ru) 2018-11-29
KR20170082653A (ko) 2017-07-14
HK1220706A1 (zh) 2017-05-12
PT2913344T (pt) 2017-11-14
HUE025435T2 (en) 2016-04-28
HRP20150656T1 (hr) 2015-07-31
HRP20171636T1 (hr) 2017-12-15
NZ627103A (en) 2016-03-31
MX361876B (es) 2018-12-18
NO2913344T3 (es) 2017-12-30
PL2398828T3 (pl) 2015-08-31
KR20210028271A (ko) 2021-03-11
CA2752584C (en) 2015-11-24
UA117807C2 (uk) 2018-10-10
JP5859314B2 (ja) 2016-02-10
UA106607C2 (uk) 2014-09-25
EP2398828B1 (en) 2015-03-25
JP6317780B2 (ja) 2018-04-25
SG10201407281UA (en) 2014-12-30
KR20190076069A (ko) 2019-07-01
SG173688A1 (en) 2011-09-29
KR20110122848A (ko) 2011-11-11
ECSP11011335A (es) 2011-12-30
KR20220025913A (ko) 2022-03-03
EP2398828A2 (en) 2011-12-28
RU2549678C2 (ru) 2015-04-27
DK2913344T3 (da) 2017-11-06
JP2020195368A (ja) 2020-12-10
CY1124849T1 (el) 2022-07-22
EP2913344B1 (en) 2017-08-02
IL214643A0 (en) 2011-11-30
US20240117073A1 (en) 2024-04-11
CN105399829A (zh) 2016-03-16
LT2913344T (lt) 2017-09-25
CO6420350A2 (es) 2012-04-16
HUE037061T2 (hu) 2018-08-28
ES2645663T3 (es) 2017-12-07
RU2018130075A (ru) 2020-02-20
PE20120569A1 (es) 2012-06-14
PE20200609A1 (es) 2020-03-10
NZ608773A (en) 2014-10-31
RU2014120536A (ru) 2015-11-27
JP2018148887A (ja) 2018-09-27
NZ716762A (en) 2017-09-29
PT2398828E (pt) 2015-06-30
MY185858A (en) 2021-06-14
CN102405235A (zh) 2012-04-04
EP2913344A1 (en) 2015-09-02
AU2017276184A1 (en) 2018-01-18
CL2011002003A1 (es) 2012-05-25
MY165583A (en) 2018-04-05
PL2913344T3 (pl) 2018-02-28
JP2015043778A (ja) 2015-03-12
EP3301117A3 (en) 2018-07-25
ES2540802T3 (es) 2015-07-13
WO2010096434A3 (en) 2011-01-27
AU2021201724A1 (en) 2021-04-15
JP2016188209A (ja) 2016-11-04
KR101809441B1 (ko) 2017-12-15
JP6199269B2 (ja) 2017-09-20
BRPI1012340B1 (pt) 2021-06-01
JP2022137018A (ja) 2022-09-21
AU2010216168A1 (en) 2011-09-29
EP3301117A2 (en) 2018-04-04
HK1214278A1 (zh) 2016-07-22
MX2018015915A (es) 2020-09-02
US20210032366A1 (en) 2021-02-04
KR20180125044A (ko) 2018-11-21
WO2010096434A2 (en) 2010-08-26
NZ595224A (en) 2013-04-26
RU2018130075A3 (es) 2022-04-29
US9072798B2 (en) 2015-07-07

Similar Documents

Publication Publication Date Title
DOP2020000032A (es) Proteínas de unión específicas y sus usos
UY32915A (es) Proteínas de únión específicas y sus usos
UY39436A (es) Proteínas de unión específicas y sus usos
CY1121148T1 (el) Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων
TN2015000396A1 (en) Antibody drug conjugates
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
PE20160953A1 (es) Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
EA201290727A1 (ru) Пирролбензодиазепины и их конъюгаты
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
CL2015000431A1 (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
PA8849001A1 (es) Anticuerpos de c-met
ECSP12011694A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2-humana
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
CO6571892A2 (es) Composiciones y métodos para el diagnostico y tratamiento de tumores
CO2019006341A2 (es) Fragmento fab novedoso de anticuerpo anti-muc1 de humano
EA201291065A1 (ru) Антитела против vla-4
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
EA201490180A1 (ru) Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний
CL2008003525A1 (es) Conjugado de anticuerpo monoclonal humano anti-rg1 o una porcion de union a antigeno del mismo con moleculas asociadas, composicion que lo comprende; metodo in vitro para inhibir el crecimiento de una celula tumoral que expresa rg-1; uso de dicho conjugado para tratar el cancer